When was GtreeBNT founded?

GtreeBNT was founded in 2000 and raised its 1st funding round 15 years after it was founded.

Where is GtreeBNT located?

GtreeBNT is headquartered in Seongnam-si, South Korea.

Is GtreeBNT a funded company?

GtreeBNT is a funded company, having raised a total of $***** in its 1st and only funding round, a Post IPO round on May 10, 2015.

When was the latest funding round of GtreeBNT?

GtreeBNT's latest funding was a $***** Post IPO round on May 10, 2015, with participation from 1 investor. Its primary sector is Oncology. In South Korea, the Oncology sector has seen $91.1M in funding in 2026 to date.

Where does GtreeBNT rank among its competitors?

GtreeBNT ranks 2720th amongst 3272 active competitors, of which 1116 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of GtreeBNT?

GtreeBNT's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Among them, Immuneel secured the most recent funding round in June, 2026.

GtreeBNT - 2026 Company Profile, Team, Funding & Competitors

GtreeBNT is an acqui-hired company based in Seongnam-si (South Korea), founded in 2000. It operates as a Developer of therapies for treating brain cancer. GtreeBNT has raised an undisclosed amount in funding. The company has 3272 active competitors, including 1116 funded and 774 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio.

Company Details

GtreeBNT is developing therapies for treating brain cancer (glioblastomas). The lead candidate of the company OKN-007 is used for treating brain cancer. It protects the nerves and decreases necrosis in brain cells by removing reactive oxygen species. It inhibits endoglucosamine-6-sulfatase. The candidate is in phase Ib clinical trial. The candidate also has received orphan drug designation from USFDA for developing therapies against glioblastoma.

Key Metrics

Founded Year

2000

Location

Seongnam-si, South Korea

Stage

Acqui-Hired

Latest Funding Round

Post IPO, May 10, 2015, $*****

Investors

E&Investment & 1 more

Ranked

2720^th among 3272 active competitors

Similar Companies

Jazz Pharmaceuticals & 2976 more

View GtreeBNT's full profile

GtreeBNT has raised funding over 1 round. Its latest funding round was a Post IPO round on May 10, 2015 for $*****. 1 investor participated in its latest round. GtreeBNT has 2 institutional investors.

Here is the list of recent funding rounds of GtreeBNT:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 10, 2015	2820895	Post IPO	3199502	8993852	4968941	9737326

Access funding benchmarks and valuations. Sign up today!

View details of GtreeBNT's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of GtreeBNT include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of GtreeBNT, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, F-Prime Capital & 23 others	71/100
2720th	GtreeBNT 2000, Seongnam-si (South Korea), Acqui-Hired	Developer of therapies for treating brain cancer	-	E&Investment, InterVest	23/100